Charles Zhou
Stock Analyst at UBS
(1.31)
# 3,500
Out of 4,902 analysts
10
Total ratings
57.14%
Success rate
-7.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $150.06 | -9.37% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $14.53 | +10.12% | 1 | Mar 8, 2023 | |
| COGT Cogent Biosciences | Initiates: Buy | $15 | $12.20 | +22.95% | 1 | Jun 28, 2022 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.54 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.33 | +4,110.53% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $1.52 | +2,926.32% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $3.22 | - | 2 | Jan 22, 2020 |
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $150.06
Upside: -9.37%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $14.53
Upside: +10.12%
Cogent Biosciences
Jun 28, 2022
Initiates: Buy
Price Target: $15
Current: $12.20
Upside: +22.95%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.54
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.33
Upside: +4,110.53%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $1.52
Upside: +2,926.32%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.22
Upside: -